Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  47,361 results for ""Antibodies, Monoclonal""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments.

  • Authors : Fofi L; Headache and Neurosonology Unit, Fondazione Policlinico Campus Bio-Medico, Rome, Italy.; Headache Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy.

Subjects: Migraine Disorders*/Migraine Disorders*/Migraine Disorders*/prevention & control ; Migraine Disorders*/Migraine Disorders*/Migraine Disorders*/drug therapy ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/therapeutic use

  • Source: Cephalalgia : an international journal of headache [Cephalalgia] 2025 Oct; Vol. 45 (10), pp. 3331024251378776. Date of Electronic Publication: 2025 Oct 17.Publisher: Sage Country of Publication: England NLM ID: 8200710 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2982

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study.

  • Authors : Liu Z; Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Subjects: Receptor, ErbB-2*/Receptor, ErbB-2*/Receptor, ErbB-2*/antagonists & inhibitors ; Receptor, ErbB-2*/Receptor, ErbB-2*/Receptor, ErbB-2*/genetics ; Receptor, ErbB-2*/Receptor, ErbB-2*/Receptor, ErbB-2*/metabolism

  • Source: BMC cancer [BMC Cancer] 2025 Sep 25; Vol. 25 (1), pp. 1432. Date of Electronic Publication: 2025 Sep 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort.

  • Authors : Wetzke M; Department of Pediatric Pneumology, Allergy, and Neonatology, Hannover Medical School, Hannover, Germany.; German Center for Lung Research, Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany.

Subjects: Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/virology ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/epidemiology ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/drug therapy

  • Source: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2025 Sep; Vol. 19 (9), pp. e70164.Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic)

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease.

Subjects: Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/drug therapy ; Amyloid beta-Peptides*/Amyloid beta-Peptides*/Amyloid beta-Peptides*/antagonists & inhibitors ; Amyloid beta-Peptides*/Amyloid beta-Peptides*/Amyloid beta-Peptides*/metabolism

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2025 Jul; Vol. 14 (7), pp. 1191-1200. Date of Electronic Publication: 2025 May 09.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review.

  • Authors : Kciuk M; Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.; Wanke K

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/metabolism ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/immunology

  • Source: Molecules (Basel, Switzerland) [Molecules] 2025 Jun 21; Vol. 30 (13). Date of Electronic Publication: 2025 Jun 21.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read Online Read More Add to Saved list
×
Academic Journal

In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma.

  • Authors : Kosharek AT; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.; Zuleger CL

Subjects: Melanoma*/Melanoma*/Melanoma*/immunology ; Melanoma*/Melanoma*/Melanoma*/veterinary ; Melanoma*/Melanoma*/Melanoma*/drug therapy

  • Source: PloS one [PLoS One] 2025 Aug 19; Vol. 20 (8), pp. e0330200. Date of Electronic Publication: 2025 Aug 19 (Print Publication: 2025).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list
×
Academic Journal

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89 Zr/ 131 I-Labeled Tinurilimab.

  • Authors : Chen C; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.; School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.

Subjects: Zirconium* ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/diagnostic imaging ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/diagnosis

  • Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2025 Jun; Vol. 12 (21), pp. e2415689. Date of Electronic Publication: 2025 Apr 03.Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Characterization of pritumumab in murine models and primate safety study.

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/pharmacology ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/adverse effects ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/drug therapy

  • Source: Scientific reports [Sci Rep] 2025 Mar 25; Vol. 15 (1), pp. 10178. Date of Electronic Publication: 2025 Mar 25.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

  • Authors : Ogdie A; University of Pennsylvania School of Medicine, 3400 Spruce St., White Building, Rm 5023, Philadelphia, PA, 19104, USA. .; Reddy SM

Subjects: Arthritis, Psoriatic*/Arthritis, Psoriatic*/Arthritis, Psoriatic*/drug therapy ; Arthritis, Psoriatic*/Arthritis, Psoriatic*/Arthritis, Psoriatic*/immunology ; Arthritis, Psoriatic*/Arthritis, Psoriatic*/Arthritis, Psoriatic*/diagnosis

  • Source: Trials [Trials] 2025 Mar 19; Vol. 26 (1), pp. 96. Date of Electronic Publication: 2025 Mar 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients.

  • Authors : Marsiglia MD; Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.; Bianchi S

Subjects: SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/immunology ; SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/genetics ; RNA, Viral*/RNA, Viral*/RNA, Viral*/blood

  • Source: PloS one [PLoS One] 2025 Apr 25; Vol. 20 (4), pp. e0321356. Date of Electronic Publication: 2025 Apr 25 (Print Publication: 2025).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  47,361 results for ""Antibodies, Monoclonal""